Trials / Recruiting
RecruitingNCT05226494
Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
A Phase 1 Trial to Evaluate the Safety and Tolerability of Fb-PMT in Patients With Recurrent Glioblastoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- Sponsor
- NanoPharmaceuticals LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Glioblastoma is a highly aggressive and fatal form of primary malignant brain tumor with limited treatment options. fb-PMT affects a large group of cancer cell signaling pathways and thus may be effective in heterogeneous, treatment-resistant tumors such as Glioblastoma. fb-PMT also is actively transported across the blood-brain barrier into the brain. This study is being conducted to determine the dose level for further clinical development of fb-PMT to treat recurrent Glioblastoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | fb-PMT | Daily dosing based on patient weight |
Timeline
- Start date
- 2022-06-23
- Primary completion
- 2026-10-01
- Completion
- 2027-10-01
- First posted
- 2022-02-07
- Last updated
- 2025-06-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05226494. Inclusion in this directory is not an endorsement.